The End Of ‘Regulatory Science’ At US FDA – The Term, Not The Idea
Executive Summary
Former Commissioner Margaret Hamburg made advancing regulatory science a centerpiece of her tenure, but it sounds like the term ‘regulatory science’ has outlived its usefulness.
You may also be interested in...
US FDA Punts To Congress On CBD: Rx Topics Remain Outside Political Spotlight
FDA is formally asking Congress to weigh in on the best approach to regulate CBD in consumer products. That provides another target for legislative attention that may mean that FDA’s core drug regulatory activities stay comfortably out of the spotlight.
The IRA And US FDA: How Will Agency View Any Drug Development Changes?
US biopharma companies are warning of significant changes in drug development priorities as they prepare for the implementation of new Medicare pricing measures enacted in 2022. Those changes will have ripple effects on the FDA, which may spark some responses.